View in EDS

P-225 - Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.

Saved in:
Bibliographic Details
Title: P-225 - Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.
Authors: Javle, M.1 (AUTHOR), Borbath, I.2 (AUTHOR), Clarke, S.3 (AUTHOR), Hitre, E.4 (AUTHOR), Louvet, C.5 (AUTHOR), Macarulla, T.6 (AUTHOR), Oh, D.7 (AUTHOR), Spratlin, J.8 (AUTHOR), Valle, J.9 (AUTHOR), Weiss, K.10 (AUTHOR), Berman, C.11 (AUTHOR), Howland, M.11 (AUTHOR), Ye, Y.11 (AUTHOR), Cho, T.11 (AUTHOR), Moran, S.11 (AUTHOR), Abou-Alfa, G.12 (AUTHOR)
Source: Annals of Oncology. 2019 Supplement, Vol. 30, piv62-iv62. 1p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 152694327
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: P-225 - Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Javle%2C+M%2E%22">Javle, M.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Borbath%2C+I%2E%22">Borbath, I.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Clarke%2C+S%2E%22">Clarke, S.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hitre%2C+E%2E%22">Hitre, E.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Louvet%2C+C%2E%22">Louvet, C.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Macarulla%2C+T%2E%22">Macarulla, T.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Oh%2C+D%2E%22">Oh, D.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Spratlin%2C+J%2E%22">Spratlin, J.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Valle%2C+J%2E%22">Valle, J.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Weiss%2C+K%2E%22">Weiss, K.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Berman%2C+C%2E%22">Berman, C.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Howland%2C+M%2E%22">Howland, M.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ye%2C+Y%2E%22">Ye, Y.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cho%2C+T%2E%22">Cho, T.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Moran%2C+S%2E%22">Moran, S.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Abou-Alfa%2C+G%2E%22">Abou-Alfa, G.</searchLink><relatesTo>12</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2019 Supplement, Vol. 30, piv62-iv62. 1p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=152694327
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/annonc/mdz155.224
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: iv62
    Titles:
      – TitleFull: P-225 - Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Javle, M.
      – PersonEntity:
          Name:
            NameFull: Borbath, I.
      – PersonEntity:
          Name:
            NameFull: Clarke, S.
      – PersonEntity:
          Name:
            NameFull: Hitre, E.
      – PersonEntity:
          Name:
            NameFull: Louvet, C.
      – PersonEntity:
          Name:
            NameFull: Macarulla, T.
      – PersonEntity:
          Name:
            NameFull: Oh, D.
      – PersonEntity:
          Name:
            NameFull: Spratlin, J.
      – PersonEntity:
          Name:
            NameFull: Valle, J.
      – PersonEntity:
          Name:
            NameFull: Weiss, K.
      – PersonEntity:
          Name:
            NameFull: Berman, C.
      – PersonEntity:
          Name:
            NameFull: Howland, M.
      – PersonEntity:
          Name:
            NameFull: Ye, Y.
      – PersonEntity:
          Name:
            NameFull: Cho, T.
      – PersonEntity:
          Name:
            NameFull: Moran, S.
      – PersonEntity:
          Name:
            NameFull: Abou-Alfa, G.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 07
              Text: 2019 Supplement
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-print
              Value: 09237534
          Numbering:
            – Type: volume
              Value: 30
          Titles:
            – TitleFull: Annals of Oncology
              Type: main
ResultId 1